• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vaxcyte, Inc. - Common Stock (NQ:PCVX)

    55.48 -0.14 (-0.25%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 876,177
    Open 55.89
    Bid (Size) 43.00 (100)
    Ask (Size) 56.68 (100)
    Prev. Close 55.62
    Today's Range 54.92 - 56.53
    52wk Range 27.66 - 76.61
    Shares Outstanding 93,706,790
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026
    As of March 9, 2026, a dramatic regime shift is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and AI-driven mega-caps, small-cap stocks have emerged as the... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Supply Chain
    Vaxcyte Inc (NASDAQ:PCVX) Reports Q4 2025 Results, Highlights Phase 3 Progress and Strong Cash Position ↗
    Via Chartmill

    Performance

    YTD
    +19.4%
    +19.4%
    1 Month
    +4.0%
    +4.0%
    3 Month
    +27.0%
    +27.0%
    6 Month
    +77.6%
    +77.6%
    1 Year
    -26.3%
    -26.3%

    More News

    Read More
    News headline image
    Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Announces Pricing of $550 Million Public Offering
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte's Chief Technical Ops Officer Sells Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    These 3 Stocks Are Using Buybacks to Signal Market Confidence ↗
    Via MarketBeat
    News headline image
    Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown ↗
    Via Benzinga
    Topics Bonds
    News headline image
    Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗
    Via Benzinga
    News headline image
    Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Vaxcyte (PCVX) Q2 Loss Widens 11% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
    From Vaxcyte, Inc.
    Via GlobeNewswire
    News headline image
    Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
    Via Benzinga
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill

    Frequently Asked Questions

    Is Vaxcyte, Inc. - Common Stock publicly traded?
    Yes, Vaxcyte, Inc. - Common Stock is publicly traded.
    What exchange does Vaxcyte, Inc. - Common Stock trade on?
    Vaxcyte, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Vaxcyte, Inc. - Common Stock?
    The ticker symbol for Vaxcyte, Inc. - Common Stock is PCVX on the Nasdaq Stock Market
    What is the current price of Vaxcyte, Inc. - Common Stock?
    The current price of Vaxcyte, Inc. - Common Stock is 55.48
    When was Vaxcyte, Inc. - Common Stock last traded?
    The last trade of Vaxcyte, Inc. - Common Stock was at 03/17/26 04:00 PM ET
    What is the market capitalization of Vaxcyte, Inc. - Common Stock?
    The market capitalization of Vaxcyte, Inc. - Common Stock is 5.20B
    How many shares of Vaxcyte, Inc. - Common Stock are outstanding?
    Vaxcyte, Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.